Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
13.07 USD | +0.12% | -1.58% | -8.12% |
May. 16 | Takeda Canada Completes LOI Stage for Post-Transplant Cytomegalovirus Treatment | MT |
May. 15 | Takeda Pharmaceutical's Dengue Vaccine Granted WHO Prequalification | MT |
Sales 2024 | 4,264B 27.2B | Sales 2025 * | 4,161B 26.54B | Capitalization | 6,481B 41.35B |
---|---|---|---|---|---|
Net income 2024 | 144B 919M | Net income 2025 * | 127B 812M | EV / Sales 2024 | 1.54 x |
Net Debt 2024 * | 3,771B 24.06B | Net Debt 2025 * | 4,125B 26.31B | EV / Sales 2025 * | 2.55 x |
P/E ratio 2024 |
45.4
x | P/E ratio 2025 * |
48.8
x | Employees | 49,095 |
Yield 2024 * |
4.53% | Yield 2025 * |
4.62% | Free-Float | 99.12% |
Latest transcript on Takeda Pharmaceutical Company Limited
1 day | +0.12% | ||
1 week | -1.58% | ||
Current month | -0.60% | ||
1 month | +0.32% | ||
3 months | -11.93% | ||
6 months | -7.10% | ||
Current year | -8.12% |
Managers | Title | Age | Since |
---|---|---|---|
Christophe Weber
CEO | Chief Executive Officer | 57 | 14-03-31 |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 45 | 22-01-31 |
Mwana Lugogo
CMP | Compliance Officer | 54 | 11-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 71 | 16-05-31 | |
Ian Clark
BRD | Director/Board Member | 62 | 18-12-31 |
Steven Gillis
BRD | Director/Board Member | 71 | 18-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-24 | 13.18 | +1.24% | 2,463 |
24-05-23 | 13.02 | -0.61% | 915 |
24-05-22 | 13.1 | -0.83% | 2,617 |
24-05-21 | 13.21 | -0.54% | 1,342 |
Delayed Quote London S.E., May 23, 2024 at 10:28 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+38.51% | 727B | |
-6.23% | 354B | |
+18.78% | 328B | |
+1.35% | 277B | |
+14.53% | 243B | |
+7.59% | 205B | |
-5.93% | 203B | |
+6.19% | 164B | |
+0.31% | 164B |
- Stock Market
- Equities
- 4502 Stock
- 0A87 Stock